Clearmind Medicine's Patent Application for Ketamine Innovations
![Clearmind Medicine's Patent Application for Ketamine Innovations](https://investorshangout.com/images/blog/ihnews-Clearmind%20Medicine%27s%20Patent%20Application%20for%20Ketamine%20Innovations.jpg)
Clearmind Medicine Announces Patent Application Publication
Clearmind Medicine Inc. (Nasdaq: CMND), a clinical-stage biotech company focused on the development of psychedelic-derived therapeutics, recently announced the publication of its patent application under the Patent Cooperation Treaty (PCT) for novel combinations involving Ketamine and N-Acylethanolamines. This significant development reflects the company's ongoing commitment to addressing some of the most pressing health challenges currently faced in the medical field.
Collaboration with SciSparc Ltd.
The patent application stems from a productive collaboration between Clearmind and SciSparc Ltd. (Nasdaq: SPRC), a specialized pharmaceutical company engaged in clinical trials for central nervous system disorders. Together, both organizations are exploring combination therapies that synergistically integrate SciSparc's Palmitoylethanolamide (PEA) with Clearmind's innovative psychedelic molecule, 5-methoxy-2-aminoindan (MEAI). The objective is to develop effective treatments for addictions, promote weight loss, and address various mental health disorders.
The Importance of Combination Therapies
The collaboration has so far resulted in the filing of thirteen patents with the U.S. Patent and Trademark Office, along with additional applications across multiple global jurisdictions. This underscores the potential for significant advancements in therapeutic options through these innovative combination therapies.
The Role of the FDA in Ketamine Treatments
Recently, the U.S. Food and Drug Administration approved a ketamine derivative as a nasal spray medication intended for adult patients suffering from depression, specifically for those who have not responded to other treatments. This FDA approval highlights the critical need for effective mental health treatments, particularly in cases involving major depressive disorder (MDD), where patients may experience suicidal thoughts or behaviors.
Usage Guidelines and Patient Safety
The approved treatment is subject to strict administration guidelines, necessitating that it be administered only at certified medical facilities alongside antidepressant medications. Patients are required to stay at the facility for a two-hour observation period after receiving a dose, which allows healthcare providers to monitor for any potential serious side effects.
Comments from Clearmind's CEO
Dr. Adi Zuloff-Shani, CEO of Clearmind, stated, "Through our collaboration with SciSparc and extensive research by their team, we have discovered that combining PEA with various compounds can potentially reduce treatment dosages while maintaining efficacy and minimizing side effects. Ketamine was approved by the FDA for supervised use due to its associated risks, including the chance of abuse and both psychological and physical dependence. Our ultimate goal is to develop safe and effective treatments that provide therapeutic benefits while minimizing adverse reactions."
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical company that focuses on discovering and developing innovative psychedelic-derived therapeutics. The company aims to address prevalent and underserved health issues, such as alcohol use disorder. Clearmind is committed to developing compounds derived from psychedelics with intentions to commercialize them as regulated medicines, food products, or supplements.
Intellectual Property and Future Goals
With an intellectual property portfolio comprising nineteen patent families and 29 granted patents, Clearmind is strategically positioned to pursue additional patents for its compounds as warranted. The company will remain opportunistic regarding opportunities to acquire additional intellectual property to strengthen its portfolio further.
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical company led by an experienced team of executives and scientists. The company is focused on developing technologies and assets based on cannabinoid pharmaceuticals. Current drug development programs include SCI-110 for treating Tourette Syndrome and SCI-210 for treating autism and status epilepticus, alongside a focus on THC and non-psychoactive cannabidiol.
Frequently Asked Questions
What is the focus of Clearmind Medicine?
Clearmind Medicine focuses on the discovery and development of psychedelic-derived therapeutics to address major under-treated health problems.
What is the recent patent application about?
The patent application involves innovative combinations of Ketamine and N-Acylethanolamines aimed at addressing mental health disorders.
Who is Clearmind's collaborator in this patent application?
Clearmind is collaborating with SciSparc Ltd., a company specialized in pharmaceutical treatments for central nervous system disorders.
What are the potential applications of the research?
The research aims to create therapies for addictions, weight loss, and various mental health issues using combination therapies.
How is the FDA involved with Ketamine treatments?
The FDA recently approved a ketamine derivative for treating patients with depression, showcasing a significant step towards effective mental health care.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- MediciNova Secures Patent Allowance for MN-166 in Post-COVID Care
- Emergent BioSolutions Approved ACAM2000® for Mpox
- Serabi Gold Announces Robust Mid-Year Financial Performance
- BEN Partners with INTERVENT and Members Only Health for AI in Healthcare
- Hudbay Receives Key Aquifer Protection Permit for Copper World
- CUBEBIO Partners with Mountain Crest V for Public Listing
- InterCure Reports Strong Financial Performance in 2024
- Pixalate Reveals Top Websites for Open Programmatic Ad Quality
- ARCpoint Conference Call for Q2 2024 Financial Results
- NVIDIA Schedules Event for Financial Community Engagement
- Pan American Energy Completes Phase 2 Earn-In for Big Mack
- Innovative Ketamine-Based Treatment Collaboration
- Kane Biotech Reports Strong Q2 2024 Financial Performance
- California Water Service Group Celebrates Top Workplace Honor
- Enviri Corporation Sells Reed Minerals for $45 Million
- ARMOUR Residential REIT Announces Dividend Rate for September 2024
- Rail Vision Releases Strong Financial Results for H1 2024
- Pulmonx to Showcase Innovations at Key Growth Conference
- SPS Commerce to Showcase Innovations at Citi's Conference
- Nvidia's Earnings Report Signals Caution for Investors
- Maximizing Savings: Tips and Top States for Savers
- Vistra Communications and IT Data Solutions Join Forces
- Market Update: Record Dow Performance Amid Earnings Reactions
- Introducing EDCXtra™: A Next-Gen Data Capture Platform
- IMCD Issues EUR 500 Million Rated Bond for Business Growth
Recent Articles
- BEN Partners with INTERVENT and Members Only Health for AI in Healthcare
- Great Lakes Dredge & Dock Corporation Upgraded to B- Rating
- ARMOUR Residential REIT Announces Dividend Rate for September 2024
- Great Elm Group Announces Fiscal 2024 Financial Results
- Oportun Achieves $223 Million in Asset-Backed Securitization
- Nokia Addresses Stock Trading Activity Concerns
- ONEOK Inc. Expands Operations with New Acquisitions
- Global Process Analytical Technology Market Insights
- Virginia Credit Union Welcomes New Board Members Post Merger
- Rezolve AI Aims for Conversational Commerce Dominance
- EDP Renewables Promotes Gabriel Yamal to EVP Role
- Investment Insights into Roblox and Palantir Technologies
- Growth of Container Security Market to USD 13.10 Billion
- Biomerica Reports Year-End Results for Fiscal 2024
- Getty Images Becomes Official Photographer for TIFF 2024
- Inozyme Pharma Set to Participate in Healthcare Conference
- How IRA Millionaires Are Growing Their Wealth
- EDAP TMS SA Highlights Participation in Investment Conference
- Pasinex Resources Reports 2024 Q2 Financial Results
- Net Asset Value of WisdomTree Funds
- Evaluating Rivian and Archer: Growth Potential and Risks
- Galantas Gold Corporation Q2 2024 Financial Results Overview
- Aircraft Rescue and Firefighting Vehicles Market Growth
- Senator Questions Intel's Job Cuts Amid Billion-Dollar Grants
- Patagonia Gold Reports Strong Q2 2024 Financial Performance